Technology
Health
Pharmaceutical

Zymeworks

$24.31
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) As of 4:30 PM EDT after-hours

Why Robinhood?

You can buy or sell Zymeworks and other stocks, options, ETFs, and crypto commission-free!

About ZYME

Zymeworks Inc., also called Zymeworks, is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. Read More The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.

Employees
183
Headquarters
Vancouver, British Columbia
Founded
2003
Market Cap
779.10M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
318.22K
High Today
$24.50
Low Today
$23.78
Open Price
$24.39
Volume
117.01K
52 Week High
$25.71
52 Week Low
$10.72

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
2017 IPO
Canada
North America

ZYME News

Financial PostJul 16

Celgene Selects Lead Oncology Therapeutic Candidate Under Bispecific Antibody Collaboration with Zymeworks

21
Financial PostJun 24

Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters' Over-Allotment Option to Purchase Additional Shares

261

ZYME Earnings

-$0.83
-$0.13
$0.58
$1.28
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 31, After Hours

More ZYME News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.